ADVANCING POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES

OCTOBER 2021

© 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL

2

Forward Looking Statements

The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (SAB) and is general background information about SAB's activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete. Information in this presentation, including financial forecasts, should not be considered advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account any particular investment objectives, financial situation or needs.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to SAB's businesses and operations, market conditions, results of operations and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements. SAB does not undertake any obligation to update any information herein for any reason or to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner and the presentation may contain errors or omissions. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside SAB's control. Past performance is not a reliable indication of future performance.

Unless otherwise specified, information is current at the date hereof, unless specifically noted.

© 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL

Novel DiversitAb™ Platform for Developing Highly-Differentiated Immunotherapies

3

Robust, growing

Vertical integration

Leveraged advanced

Established

Strong corporate

clinical-stage

enables rapid,

genetic engineering

proof-of-concept

position with

pipeline spanning

scalable

& antibody science

through US

experienced

multiple

development

to develop

Government funded

leadership team

therapeutic areas

of multi-targeted

Tc bovine-derived

programs &

and growing

with multiple

products

fully-human

partnerships totaling

infrastructure

near-term catalysts

polyclonal

~$300MM

antibodies

Innovative DiversitAb™ platform produces a new class of targeted fully-human,highly-potent polyclonal antibodies

© 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL

4

Versatile Antibody Platform with Ability to Capture Multiple Markets

Human Antibody Discovery & Development Engine, New Source for IgG, Therapeutic Production

Represents Multibillion-Dollar Market Opportunity

Polyclonal Antibody Development

Human Immunoglobulin

Reagent Antibodies (Diagnostics)

Monoclonal Antibody Discovery

-Human, targeted, high-potency-Multivalent,multi-targeted

-Offers large scale, consistently managed donor pool, genetically representing single human donor

-Fully Human -Rapid development -Specifically targeted

-Larger volume of antibodies -Greater diversity; higher affinity -Robust (ruminant) immune response

  • Robust pipeline across multiple therapeutic areas
  • Potential to capture mAb, hIVIG, animal pAb markets and address unmet needs
  • In vivo data demonstrating comparability
    to approved SC product and potential benefits over human-derived
  • Current worldwide standard for Ebola and MERS
  • Low volume and high margin, unique capability
  • Multiple ongoing global pharma collaborations

© 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL

5

Polyclonals: Broader Spectrum Efficacy Valuable in Range of Indications

FDA: CENTER FOR DRUG EVALUATION & RESEARCH (CDER)

FDA: CENTER FOR BIOLOGICS EVALUATION & RESEARCH (CBER)

Characterized

Plasma-Derived

Monoclonal Antibody

Polyclonal

Antibodies

TARGET

TARGET

mAb

Clones of a single antibody bind to a specific epitope

Monoclonal Approach

  • Highly-targetedwith specific activity
  • Iterative Ab identification and selection process
  • Selected and cloned in vitro
  • May promote escape mutants via selective pressure
  • Resistance may develop as pathogen/target mutates
  • Current cocktail trend to address resistance

pAbs

Natural mixture of many antibodies bind to multiple epitopes

Polyclonal Approach

  • Diversity of antibodies with multiple modalities
  • Naturally selected and produced in vivo
  • Effective against escape mutants
  • Reduced possibility of resistance
  • Activates cellular immunity
  • Synergistic properties not duplicated by mono- or oligoclonals

© 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

SAB Biotherapeutics Inc. published this content on 15 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 14:55:01 UTC.